The Sphingosine Kinase 2 Inhibitor ABC294640 Restores the Sensitivity of BRAFV600E Mutant Colon Cancer Cells to Vemurafenib by Reducing AKT-Mediated Expression of Nucleophosmin and Translationally-Controlled Tumour Protein

Vemurafenib (PLX4032), small-molecule inhibitor of mutated BRAFV600E protein, has emerged as a potent anti-cancer agent against metastatic melanoma harboring BRAFV600E mutation. Unfortunately, the effect of PLX4032 in the treatment of metastatic BRAF mutated colorectal cancer (CRC) is less potent du...

Descripción completa

Detalles Bibliográficos
Autores principales: Grbčić, Petra, Eichmann, Thomas O., Kraljević Pavelić, Sandra, Sedić, Mirela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509245/
https://www.ncbi.nlm.nih.gov/pubmed/34639107
http://dx.doi.org/10.3390/ijms221910767

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509245/
https://www.ncbi.nlm.nih.gov/pubmed/34639107
http://dx.doi.org/10.3390/ijms221910767

Ejemplares similares